Clinical TrialNov 12, 2026, 08:02 AM
Aktis Oncology Advances Clinical Trials for AKY-1189 and AKY-2519
AI Summary
Aktis Oncology reported progress on its two clinical-stage programs, AKY-1189 and AKY-2519. The company initiated its third Phase 1b clinical trial, BActinium-2, for AKY-2519, expanding its evaluation to lung cancer and other B7-H3 expressing tumors. Aktis also started backfill cohorts in ongoing Phase 1b trials for both AKY-1189 and AKY-2519. Preliminary data for AKY-1189 is anticipated in Q1 2027, and for AKY-2519 in 2027. The company also operationalized its in-house GMP facility, expected to supply clinical trials in the first half of 2027. Financial results for Q3 2026 showed a cash position of $492.9 million, increased collaboration revenue, higher R&D expenses, and a net loss of $29.9 million.
Key Highlights
- Aktis Oncology initiated its third Phase 1b clinical trial, BActinium-2, evaluating AKY-2519 for lung cancer and other B7-H3 expressing tumors.
- The company started first backfill cohorts in ongoing Phase 1b trials for AKY-1189 (NECTINIUM-2) and AKY-2519 (BActinium-1).
- Preliminary data for AKY-1189 is expected in Q1 2027, and for AKY-2519 in 2027.
- Aktis operationalized its in-house GMP facility at 17 Drydock, Boston, expected to supply clinical trials in H1 2027.
- Cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026, expected to fund operations into 2029.
- Collaboration revenue increased to $3.9 million for Q3 2026, up from $1.6 million in the prior year period, due to Eli Lilly collaboration.
- R&D expenses rose to $32.1 million for Q3 2026, from $16.5 million in Q3 2025, driven by clinical trial advancements.
- Net loss for Q3 2026 was $29.9 million, compared to $15.5 million in the prior-year period.
Price Impact
More from AKTS